Rates of mental illness among young people remain elevated, and the utilization of youth mental health services is expected to increase. Yet, there is limited knowledge on real-world medication usage and prescribing at these services. Hence, the aim of this study was to explore the medication prescribing patterns at a headspace center, an Australian youth mental health service.
Methods:
A retrospective cross-sectional study of medical records was conducted. Demographic data, clinical information, prescribed medications, and reasons for use of young people who attended an intake assessment at headspace Camperdown over a 13-month period, February 2021–February 2022, were analyzed. Data collection focused on medication molecule, strength, dose, prescriber designation, and indication. Data were analyzed descriptively.
Results:
Records for 608 participants were included. The median age at intake was 19.9 years old (interquartile range: 16.1–22.4), and most participants identified as female (n = 372, 61.2%). Anxiety (n = 246, 40.5%) and low mood (n = 95, 15.6%) were the most common presenting concerns. Almost half of participants (n = 291, 47.9%) reported using medication/s at intake, and almost one in five participants (n = 119, 19.6%) were prescribed a medication at the service. The most prescribed medications at headspace were melatonin (24.0%) and quetiapine (12.3%), as well as the antidepressants escitalopram (15.1%), sertraline (11.2%), and fluoxetine (7.3%).
Conclusions:
This study provides insights into the prescribing practices at a single headspace center. Further investigations are needed to explore the impacts of off-label prescribing for young people, particularly in relation to melatonin and quetiapine, where safety and efficacy in young people have not been well established.
Get full access to this article
View all access options for this article.
References
1.
American Psychiatric Association. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders. 5th ed.. American Psychiatric Association; 2013.
2.
AndersonSL and Vande GriendJP. Quetiapine for insomnia: A review of the literature. Am J Health Syst Pharm, 2014; 71(5):394–402; doi: 10.2146/ajhp130221
3.
AndrewsG, BellC, BoyceP, et al.Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the treatment of panic disorder, social anxiety disorder and generalised anxiety disorder. Aust N Z J Psychiatry, 2018; 52(12):1109–1172; doi: 10.1177/0004867418799453
Australian Medicines Handbook Pty Ltd. Australian Medicines Handbook 2023. Australian Medicines Handbook Pty Ltd; Adelaide. 2023.
6.
BarczykZA, RucklidgeJJ, EgglestonM, et al.Psychotropic medication prescription rates and trends for New Zealand children and adolescents 2008–2016. J Child Adolesc Psychopharmacol, 2020; 30(2):87–96; doi: 10.1089/cap.2019.0032
7.
BoafoA, GreenhamS, SullivanM, et al.Medications for sleep disturbance in children and adolescents with depression: A survey of Canadian child and adolescent psychiatrists. Child Adolesc Psychiatry Ment Health, 2020; 14(1):10; doi: 10.1186/s13034-020-00316-8
8.
BrettJ, KarangesEA, DanielsB, et al.Psychotropic medication use in Australia, 2007 to 2015: Changes in annual incidence, prevalence and treatment exposure. Aust N Z J Psychiatry, 2017; 51(10):990–999; doi: 10.1177/0004867417721018
9.
BrimblecombeN, KnappM, MurguiaS, et al.The role of youth mental health services in the treatment of young people with serious mental illness: 2-year outcomes and economic implications. Early Interv Psychiatry, 2017; 11(5):393–400; doi: 10.1111/eip.12261
10.
CleareA, ParianteCM, YoungAH, et al.Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2008 British Association for Psychopharmacology guidelines. J Psychopharmacol, 2015; 29(5):459–525; doi: 10.1177/0269881115581093
11.
CoeHV and HongIS. Safety of low doses of quetiapine when used for insomnia. Ann Pharmacother, 2012; 46(5):718–722; doi: 10.1345/aph.1Q697
12.
DeeksLS, NauntonM, PetersonGM, et al.Pharmacists in Australian general practice: Discussion of the findings of an evaluation from 2016 to 2021. J Pharm Pract Res, 2023; 53(5):271–281; doi: 10.1002/jppr.1878
DharniA and CoatesD. Psychotropic medication profile in a community youth mental health service in Australia. Child Youth Serv Rev, 2018; 90:8–14; doi: 10.1016/j.childyouth.2018.05.007
15.
Edemann-CallesenH, AndersenHK, UssingA, et al.Use of melatonin in children and adolescents with idiopathic chronic insomnia: a systematic review, meta-analysis, and clinical recommendation. EClinicalMedicine, 2023; 61; 102048; doi: 10.1016/j.eclinm.2023.102048
16.
Ferracioli-OdaE, QawasmiA and BlochMH. Meta-analysis: melatonin for the treatment of primary sleep disorders. PLoS One, 2013; 8(5):e63773; doi: 10.1371/journal.pone.0063773
17.
FitzgeraldRJ. Medication errors: the importance of an accurate drug history. Br J Clin Pharmacol, 2009; 67(6):671–675; doi: 10.1111/j.1365-2125.2009.03424.x
18.
GrissingerM. Is an Indication-Based Prescribing System in Our Future? P t, 2019; 44(5):232–266.
19.
HändelMN, AndersenHK, UssingA, et al.The short-term and long-term adverse effects of melatonin treatment in children and adolescents: A systematic review and GRADE assessment. EClinicalMedicine, 2023; 61:102083; doi: 10.1016/j.eclinm.2023.102083
20.
HarrisPA, TaylorR, ThielkeR, et al.Research electronic data capture (REDCap)–a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform, 2009; 42(2):377–381; doi: 10.1016/j.jbi.2008.08.010
21.
HartzI, FuruK, BratlidT, et al.Hypnotic drug use among 0-17 year olds during 2004-2011: a nationwide prescription database study. Scand J Public Health, 2012; 40(8):704–711; doi: 10.1177/1403494812464446
22.
HartzI, HandalM, TverdalA, et al.Paediatric off-label use of Melatonin–A register linkage study between the Norwegian prescription database and patient register. Basic Clin Pharmacol Toxicol, 2015; 117(4):267–273; doi: 10.1111/bcpt.12411
23.
HawkeLD, MehraK, SettipaniC, et al.What makes mental health and substance use services youth friendly? A scoping review of literature. BMC Health Serv Res, 2019; 19(1):257; doi: 10.1186/s12913-019-4066-5
HetrickSE, McKenzieJE, BaileyAP, et al.New generation antidepressants for depression in children and adolescents: A network meta-analysis. Cochrane Database Syst Rev, 2021; 5(5):Cd013674; doi: 10.1002/14651858.CD013674.pub2
26.
HickieIB, ScottEM, HermensDF, et al.Applying clinical staging to young people who present for mental health care. Early Interv Psychiatry, 2013; 7(1):31–43; doi: 10.1111/j.1751-7893.2012.00366.x
27.
IBM Corp. IBM SPSS Statistics for Mac. 24.0 ed. IBM Corp: Armonk, NY; 2016.
28.
JormAF. How effective are 'headspace' youth mental health services? Aust N Z J Psychiatry, 2015; 49(10):861–862; doi: 10.1177/0004867415608003
29.
KarangesEA, StephensonCP and McGregorIS. Longitudinal trends in the dispensing of psychotropic medications in Australia from 2009–2012: Focus on children, adolescents and prescriber specialty. Aust N Z J Psychiatry, 2014; 48(10):917–931; doi: 10.1177/0004867414538675
30.
KarstenJ, HagenauwLA, KamphuisJ, et al.Low doses of mirtazapine or quetiapine for transient insomnia: A randomised, double-blind, cross-over, placebo-controlled trial. J Psychopharmacol, 2017; 31(3):327–337; doi: 10.1177/0269881116681399
31.
KellyM, DornanT and PringsheimT. The lesser of two evils: A qualitative study of quetiapine prescribing by family physicians. CMAJ Open, 2018; 6(2):E191–Ee196; doi: 10.9778/cmajo.20170145
32.
KimS, LeeG, KimE, et al.Quetiapine misuse and abuse: Is it an atypical paradigm of drug seeking behavior? J Res Pharm Pract, 2017; 6(1):12–15; doi: 10.4103/2279-042x.200987
33.
KlauJ, BernardoCDO, Gonzalez-ChicaDA, et al.Trends in prescription of psychotropic medications to children and adolescents in Australian primary care from 2011 to 2018. Aust N Z J Psychiatry, 2022; 56(11):1477–1490; doi: 10.1177/00048674211067720
34.
LeeSKM, SmithL, TanECK, et al.Melatonin use in children and adolescents: A scoping review of caregiver perspectives. Sleep Med Rev, 2023; 70:101808; doi: 10.1016/j.smrv.2023.101808
35.
MalhiGS, BellE, BassettD, et al.The 2020 royal Australian and New Zealand college of psychiatrists clinical practice guidelines for mood disorders. Aust N Z J Psychiatry, 2021; 55(1):7–117; doi: 10.1177/0004867420979353
36.
McGorryPD, TantiC, StokesR, et al.headspace: Australia's national youth mental health foundation—where young minds come first. Med J Aust, 2007; 187(S7):S68–S70; doi: 10.5694/j.1326-5377.2007.tb01342.x
MurshidMA and MohaidinZ. Models and theories of prescribing decisions: A review and suggested a new model. Pharm Pract (Granada), 2017; 15(2):990; doi: 10.1854/9/PharmPract.2017.02.990
NguyenT, SeilerN, BrownE, et al.The effect of Clinical Practice Guidelines on prescribing practice in mental health: A systematic review. Psychiatry Res, 2020; 284:112671; doi: 10.1016/j.psychres.2019.112671
42.
ParensE and JohnstonJ. Understanding the agreements and controversies surrounding childhood psychopharmacology. Child Adolesc Psychiatry Ment Health, 2008; 2(1):5; doi: 10.1186/1753-2000-2-5
43.
RasmussenL, PrattN, RougheadE, et al.Prevalence of psychotropic medicine use in Australian children with autism spectrum disorder: A drug utilization study based on children enrolled in the longitudinal study of Australian children. J Autism Dev Disord, 2019; 49(1):227–235; doi: 10.1007/s10803-018-3718-3
44.
RickwoodD, McEachranJ, SawA, et al.Sixteen years of innovation in youth mental healthcare: Outcomes for young people attending Australia's headspace centre services. PLoS One, 2023; 18(6):e0282040; doi: 10.1371/journal.pone.0282040
45.
RickwoodDJ, MazzerKR, TelfordNR, et al.Changes in psychological distress and psychosocial functioning in young people visiting headspace centres for mental health problems. Med J Aust, 2015; 202(10):537–542; doi: 10.5694/mja14.01696
46.
RickwoodDJ, TelfordNR, ParkerAG, et al.headspace - Australia's innovation in youth mental health: who are the clients and why are they presenting? Med J Aust, 2014; 200(2):108–111; doi: 10.5694/mja13.11235
47.
SansoneRA and SansoneLA. Is seroquel developing an illicit reputation for misuse/abuse? Psychiatry (Edgmont), 2010; 7(1):13–16.
48.
SchiffGD, Seoane-VazquezE and WrightA. Incorporating indications into medication ordering–time to enter the age of reason. N Engl J Med, 2016; 375(4):306–309; doi: 10.1056/NEJMp1603964
49.
SchlackR, PeerenboomN, NeuperdtL, et al.The effects of mental health problems in childhood and adolescence in young adults: Results of the KiGGS cohort. J Health Monit, 2021; 6(4):3–19; doi: 10.2564/6/8863
ShahC, UmaruN, AdamsE, et al.Assessing the integration of pharmacist independent prescribers in child and adolescent mental health services. Pharm J, 2021; 306; doi: 10.1211/PJ.2021.1.45513
52.
SimsR, MichaleffZA, GlasziouP, et al.Consequences of a diagnostic label: A systematic scoping review and thematic framework. Front Public Health, 2021; 9:725877; doi: 10.3389/fpubh.2021.725877
TsaiC-Y, YangH-C, IslamM, et al.Psychotropic medications prescribing trends in adolescents: A nationwide population-based study in Taiwan. Int J Qual Health Care, 2017; 29(6):861–866; doi: 10.1093/intqhc/mzx123
60.
VitielloB, CorrellC, van Zwieten-BootB, et al.Antipsychotics in children and adolescents: increasing use, evidence for efficacy and safety concerns. Eur Neuropsychopharmacol, 2009; 19(9):629–635; doi: 10.1016/j.euroneuro.2009.04.008
61.
WHO Collaborating Centre for Drug Statistics Methodology. The Anatomical Therapeutic Chemical (ATC) classification system and the Defined Daily Dose (DDD) Index 2023. 2023. https://www.whocc.no/atc_ddd_index/ [October 10, 2023].
62.
WolraichML. Annotation: The use of psychotropic medications in children: an American view. J Child Psychol Psychiatry, 2003; 44(2):159–168; doi: 10.1111/1469-7610.00110
63.
WoodSJ, IlomäkiJ, GouldJ, et al.Dispensing of psychotropic medications to Australian children and adolescents before and during the COVID-19 pandemic, 2013–2021: A retrospective cohort study. Med J Aust, 2023; 219(1):18–25; doi: 10.5694/mja2.51948
